CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.
Early diagnosis of Alzheimer's disease is important in initiating symptomatic treatment with acetylcholine esterase inhibitors, and will be of even greater significance if drugs with a potential to slow down the degenerative process, such as beta-secretase inhibitors and beta-amyloid vaccination, prove to have a clinical effect. During the last decade, research efforts have focused on developing cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease. In this review, the background and principles for, and the diagnostic performance of, the CSF biomarkers total tau, phosphorylated tau and the 42-amino acid form of beta-amyloid, are reviewed. New candidate CSF biomarkers and new strategies, including multiparameter immunoassays and CSF proteomics techniques, in the search of additional CSF biomarkers are also reviewed. Finally, the rationale for the use of CSF biomarkers to identify and monitor the biochemical effect of new drug candidates is reviewed.
Blennow
Kaj
K
The Sahlgrenska Academy at Göteborg University, Department of Clinical Neuroscience, Section of Experimental Neuroscience, Sahlgrenska University Hospital, SE-431 80 Mölndal, Sweden. kaj.blennow@neuro.gu.se
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003071:Cognition; D006801:Humans; D009448:Neurochemistry; D016896:Treatment Outcome
D016229:Amyloid beta-Peptides; D015415:Biomarkers